Wissen schafft Zukunft.

  Klinik und Poliklinik
  für RadioOnkologie
  und Strahlentherapie

  Univ.-Prof. Dr. med.
  Stephanie E. Combs

  Klinikum rechts der Isar
  Technische Universität München
  Ismaninger Str. 22
  D - 81675 München


GLIAA Studie

Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme - a randomised phase II trial

This study is designed to test if a radiotherapy target volume delineation based on Amino-acid PET (AA-PET) leads to an improvement in progression free survival in patients with recurrent GBM treated with re-irradiation, compared to target volume delineation based on Gadolinium contrast enhanced T1 weighted Magnetic Resonance Imaging (T1Gd-MRI).


Inclusion criteria

  • Local recurrence of GBM (WHO grade IV) and either not eligible for tumor resection or with macroscopic residual tumor after resection of recurrent GBM
  • Histological confirmation of GBM at initial or secondary diagnosis
  • Previous radiation therapy of the primary with a maximal total dose 59-60 Gy
  • At least 6 months since the end of pre-irradiation
  • Recurrent tumor visible on AA-PET and T1Gd-MRI with the diameter measuring 1cm to 6cm by either technique
  • Target volume definition possible according to both study arms
  • Start of re-irradiation possible within 2 weeks from FET-PET and MRI
  • Patient's written IC obtained on the day of FET-PET acquisition or latest the day after FET-PET acquisition
  • Legal capacity
  • Karnofsky Performance Score (KPS) > 60%
  • Age ≥18 years (no upper limit of age)
  • Registration

Exclusion criteria

  • No histological confirmation of GBM
  • Recent (≤4 weeks before IC) histological result showing no tumor recurrence
  • No prior radiation treatment to the primary tumor
  • More than 2 previous chemotherapy regimes or previous treatment with Avastin or other molecular targeted therapies
  • Technical impossibility to use MRI or FET-PET for Radiation Therapy (RT)-planning
  • Less than 2 weeks between application of chemotherapy and planned start of re-irradiation
  • Less than 3 weeks between resection of recurrent GBM and planned start of re-irradiation
  • Chemotherapy or molecular targeted therapies planned during re-irradiation
  • Additional chemotherapy or molecular targeted therapy or further surgery planned before diagnosis of further tumor progression after study intervention
  • Female patients of childbearing potential who are pregnant or breast feeding
  • Fertile patients refusing to use safe contraceptive methods during the study
  • Known allergy against the MRI contrast agent Gadolinium or the PET tracer 18F FET or against any of the components

In Kooperation mit

Institut für Strahlenmedizin

Logo der ESTRO


07.06.2021: We are looking for a PhD student (m/f/d). Topic "Analysis of the mechanism of Microbeam Radiation Therapy"  More: Stellenausschreibungen

07.06.2021: Bereichern Sie unser Team! Als: MTRA (m/w/d). Mehr dazu: Stellenausschreibungen

12.11.2020: Zwei Studentinnen des MSc Radiation Biology erhalten ein Stipendium des Marie-Sklodowska-Curie Fellowship Programme der International Atomic Energy Agency(IAEA): Mehr dazu: Aktuelles

03.11.2020: Kommen Sie in unser Team! - Wir suchen Sie als:
Assistenzarzt (m/w/d) als Physician Scientist (m/w/d).
Mehr dazu: Stellenausschreibungen


Univ.-Prof. Dr. med. Stephanie E. Combs
zu Gast im "alpha-thema Gespräch: Krebsbehandlung heute" bei ARD alpha und abrufbar in der Mediathek.  
Mehr dazu: Aktuelles

02.09.2020: Wir suchen Sie! - Stellenanzeige: MTRA (m/w/d): Mehr dazu: Stellenausschreibungen

01.07.2020: Neues Programm zum ASPO-Symposium über aktuelle Standards und Perspektiven in der Onkologie online:
Information zu COVID-19

Mehr dazu: Download

09.04.2020: Aktuelle Informationen für unsere Patienten zu COVID-19 von Prof. Dr. med. Stephanie E. Combs als PDF-Datei: Download
Information zu COVID-19




Medizinische Schreibkraft (m/w/d) Sekretärin (m/w/d) im Gesundheitswesen in Voll- oder Teilzeit